, Volume 8, Supplement 1, pp 28–32 | Cite as

The Indirect Costs of Morbidity in Type II Diabetic Patients

  • Ulf Persson


In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of premature retirement for both insulin-dependent diabetes mellitus (IDDM, type I diabetes) or non-insulin-dependent diabetes mellitus (NIDDM, type II diabetes) patients was twice that of the average population. Insulin-treated subjects also had twice as many sickness benefit days. The excess costs of production losses as a result of morbidity in people aged 20 to 64 years with type II diabetes were about $US7000 per individual and year. Most of these excess costs were attributed to permanent disability in the 40- to 64-year age groups.


Production Loss Excess Cost Permanent Disability Sickness Benefit Disable Individual 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Olsson J, Persson U, Tollin C, et al. Comparison of excess costs of care and production losses because of morbidity in diabetic patients. Diabetes Care 1994; 17: 1257–63PubMedCrossRefGoogle Scholar
  2. 2.
    Olsson J, ToBin C, Melander A. Intercommunity variations in antidiabetic drug utilisation and in prevalence of diabetes mellitus. Pharmacoepidemiol Drug Saf 1994; 3: 215–21CrossRefGoogle Scholar
  3. 3.
    Lindgren B. Cost of illness in Sweden 1964–1975. Lund Economic Studies: Lund, Sweden: 1981Google Scholar
  4. 4.
    Statistics Sweden: Income distribution survey in 1990. Stockholm, 1992 (Be 21 SN 9201)Google Scholar
  5. 5.
    Jonsson B, Persson U. Diabetes: A study in health economics. Lund, Sweden, The Swedish Institute for Health Economics, 1981 (!HE report 1981:7)Google Scholar
  6. 6.
    Huse D, Oster G, Killen A, et al. The economic costs of noninsulin dependent diabetes mellitus. JAMA 1989; 262: 2708–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Ulf Persson
    • 1
  1. 1.The Swedish Institute for Health EconomicsLundSweden

Personalised recommendations